KARS1 encodes lysyl-tRNA synthetase 1, a multifunctional aminoacyl-tRNA synthetase responsible for ligating lysine to its cognate tRNA 1. The enzyme exists as both cytosolic and mitochondrial isoforms that function within the multi-tRNA synthetase complex 2, where it interacts with auxiliary proteins through leucine zipper motifs. Beyond translation, KARS1 has emerged as a secreted pro-inflammatory mediator; oscillatory shear stress upregulates KARS1 expression, triggering its release via secretory autophagy, where secreted KARS1 promotes atherogenesis by inhibiting endothelial signaling and functioning as a proinflammatory paracrine molecule 3. Biallelic KARS1 mutations cause a rare syndromic disorder characterized by early-onset developmental delay, sensorineural hearing loss, progressive neurological abnormalities, and white matter involvement 14. Additional phenotypes include congenital microcephaly, seizures, oculo-motor dysfunction, and cerebellar atrophy 5. Loss-of-function studies in zebrafish reveal p53-dependent apoptosis and downregulation of neurodevelopmental genes, suggesting p53 inhibition as a therapeutic target 1. Immunological complications including B cell lymphopenia, hypogammaglobulinemia, and recurrent infections occur in a subset of patients, linked to impaired mitochondrial function in B cells 6. In cancer, elevated KARS1 associates with worse prognosis through membrane interactions with the 67-kDa laminin receptor 7.